VVV. E. Vinogradov

V. E. Vinogradov

*This is an algorithmically generated author record based on publicly available information.

V. E. Vinogradov has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Features of calcium-phosphorus metabolism and vitamin D metabolism in patients with chronic kidney disease at predialysis stages during bolus cholecalciferol therapy

    by A. S. Bondarenko, L. Ya. Rozhinskaya, A. Yu. Zhukov, V. A. Ioutsi, M. V. Ovcharov, G. S. Kolesnikova, A. I. Sleptsova, N. P. Trubitsyna, V. E. Vinogradov, O. N. Kotenko, et al.

    Background . Chronic kidney disease (CKD) is associated with disturbances in calcium-phosphate homeostasis and vitamin D metabolism, leading in mineral and bone disorders (CKD-MBD). However, the pathogenetic features of these alterations at predialysis CKD stages and the effects of high-dose cholecalciferol therapy remain insufficiently characterized. Objective . To compare vitamin D metabolites and calcium-phosphate metabolism parameters in patients with predialysis CKD and individuals without impaired kidney function, and to assess their dynamics after a single bolus dose of 150,000 IU of cholecalciferol. Materials and Methods . The study included 58 participants: 23 patients with CKD stage C3, 14 with CKD stages C4-5, and 21 controls. Parameters of calcium-phosphate metabolism and vitamin D metabolites were assessed at baseline and 7 days after a single oral dose of aqueous cholecalciferol (150,000 IU). Vitamin D metabolites were measured using LC–MS/MS. Results . Data are presented as follows: control group, CKD C3, CKD C4-5. At baseline, CKD patients had higher parathyroid hormone (PTH) levels (51.3 [40.6; 62.7] vs 70.9 [49.0; 105.9] vs 101.0 [91.7; 120.1] pg/mL), lower calcitriol concentrations (40.9 [34.3; 59.4] vs 25.0 [19.8; 29.1] vs 26.4 [13.8; 30.6] pg/mL), a trend toward higher fibroblast growth factor 23 (FGF-23) levels (0.73 [0.43; 1.07] vs 1.08 [0.61; 2.52] vs 3.22 [1.78; 4.51] pmol/L), and a reduced 24,25 (OH) 2 D 3 /25(OH)D 3 ratio (0.06 [0.04; 0.08] vs 0.03 [0.01; 0.04] vs 0.03 [0.02; 0.04]), indicating impaired 24-hydroxylase activity. Total and free 25(OH)D levels and vitamin D-binding protein (VDBP) were comparable between groups. Seven days after cholecalciferol administration, a similar increase in total 25(OH)D 3 , 3-epi-25(OH)D 3 , and 24,25(OH) 2 D 3 was observed in all groups. However, the increase in free 25(OH)D was significantly smaller in CKD C3 and C4-5 compared with controls ( p =0.036 and p =0.028). PTH decreased in CKD C3 ( p =0.039), whereas FGF-23 increased in CKD C4-5 ( p =0.042). Serum calcium, phosphorus, calcitriol, and VDBP remained unchanged. Conclusion . Alterations in calcium-phosphate and vitamin D metabolism at predialysis CKD stages show a sequential pattern. Reduced vitamin D activation and inactivation, increased FGF-23 levels, and a blunted free 25(OH)D response to bolus cholecalciferol indicate specific regulatory features and limit the applicability of standard vitamin D correction regimens in this population.

  • Open Access

    Efficacy and Safety of Sglt-2 Inhibitors In Renal Allograft Recipients: an Open-Label, Single-Center Prospective Study

    by M. S. Novikova, L. O. Minushkina, S. S. Allazova, D. A. Zateyshchikov, O. I. Boeva, O. N. Kotenko, V. E. Vinogradov, E. M. Shilov, M. B. Antsiferov, O. M. Koteshkova, et al.

    Aim To evaluate the safety and efficacy of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) inhibitor therapy in kidney transplant recipients (KTRs) with and without post-transplant diabetes mellitus (PTDM). Material and methods KTRs (n=2146, with PTDM n=303, or 14%) who had undergone transplantation more than one year ago, with stable graft function (estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m2), after excluding patients with combined kidney and pancreas transplantation (n=57), type 1 diabetes mellitus (DM) (n=124), and type 2 DM diagnosed before kidney allotransplantation (KAT) (n=74), were prescribed SGLT-2i (empagliflozin 25 mg/day or dapagliflozin 10 mg/day; n=107), the rest of the KTRs (n=1784) did not receive SGLT-2i. After pseudo-randomization, two groups were formed and included in an open, single-center prospective study: an experimental group with SGLT-2i (n=78; with PTDM n=45) and a control group, without SGLT-2i (n=78; n=45 with PTDM). The groups were comparable in the PTDM duration and the period from KAT to inclusion in the study, as well as in clinical characteristics, including gender, age, history of acute myocardial infarction (AMI) before KAT, levels of glycated hemoglobin (HbA1c), systolic blood pressure (SBP) and diastolic blood pressure (DBP), GFR, microalbuminuria (MAU), blood uric acid concentration, blood lipid profile (total cholesterol (TC), low-density lipoproteins (LDL)), basal blood concentration (C0) of calcineurin inhibitors (CNI), and therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), statins, and metformin (p >0.05). Results The relative risk (RR) of all-cause death in the experimental group was reduced by 60% compared with the control group (RR 0.40; 95% confidence interval (CI) 0.17-0.98 vs. RR 2.44; 95% CI 1.01-5.86; p=0.04). The RR of adverse coronary outcomes in the experimental group was reduced by 75% compared with the control group (RR 0.25; 95% CI 0.06-0.89 vs. 4.0; 95% CI 1.11-14.42; p=0.03). The RR of adverse renal outcomes in the experimental group was reduced by 72% compared with the control group (RR 0.28; 95% CI 0.09-0.85 vs. 3.50; 95% CI 1.16-10.49; p=0.02). In addition, in the experimental group, compared to the control group, the GFR decline was slower (-1.29±0.763 ml/min/1.73 m2/year vs. -3.33±0.767 ml/min/1.73 m2/year; p=0.047). Also, a pronounced advantage in the dynamic decline in GFR was observed throughout the entire study period (-3.10±1.73 ml/min/1.73 m2 vs. -7.87±1.87 ml/min/1.73 m2; p=0.040). Conclusion SGLT2i effectively reduce cardiovascular and renal mortality, the risk of adverse renal and coronary outcomes, and slow the progression of chronic kidney disease in KTRs, regardless of the presence of PTDM. A large-scale study evaluating the efficacy of SGLT2i in KTRs is warranted to formulate appropriate clinical recommendations.

  • Evaluation of the results and cost of drug therapy for anemia in patients with 5th stage of the chronic kidney disease receiving hemodialysis in the real clinical practice in Moscow

    by O.N. Kotenko, L.V. Abolyan, N.G. Shamshurina, V.YU. Kuteinikov, V.E. Vinogradov, E.G. Dorofeeva

    Objective. To evaluate the results of drug therapy for anemia in patients with stage 5 chronic kidney disease (CKD-5) receiving hemodialysis, the prescriptions, and the cost of drug therapy for anemia in real-world settings in Moscow. Materials and methods. The study included 532 patients with CKD-5 on hemodialysis. In the first stage, the medical and demographic characteristics of patients were studied, as well as the prescriptions for erythropoiesis-stimulating agents (ESAs) — short- and long-acting erythropoietins (EPO), and iron supplements, the cost of drug products (DP) and the level of hemoglobin. In the second stage, clinical and economic analysis of «the cost-effectiveness» of drug therapy for anemia in three groups of patients receiving epoetin alfa (Eralfon), darbepoetin alfa (Aranesp) and methoxy polyethylene glycol-epoetin beta (Mircera) was carried out. The cost of ESAs, iron formulations, and intravenous injections of ESAs was considered. Hemoglobin levels, health-related quality of life, satisfaction, and treatment adherence were analyzed. The study period was from August 2021 to March 2022. Results. We identified the most commonly used drugs for treating anemia and determined their cost structure. The average drug cost for treating 1 patient with CKD-5 on hemodialysis was 82.595.94 rubles per year (for 2021). A comparative estimate of the cost of drug therapy with EPO drugs is given. «Cost-effectiveness analysis» showed that epoetin beta (Mircera) is the least expensive per «unit of effect». Conclusion. The data obtained can be used as objective information when making decisions about the medical treatment of anemia in patients with chronic kidney disease on hemodialysis, considering the clinical efficacy of drugs, their cost, and their impact on quality of life.


  • Open Access

    Anemia and quality of life of chronic kidney disease patients on renal replacement therapy by programmed hemodialysis

    by O N Kotenko, L V Abolyan, V I Kuteinikov, V E Vinogradov, V V Fomin

    Aim. To study relationship between anemia and health-related quality of life (HRQOL) of chronic kidney disease stage 5 patients (CKD) undergoing renal replacement therapy by programmed hemodialysis. Materials and Methods. The study was conducted on the basis of dialysis centers/departments in Moscow. The Russian-language version of the KDQOL-SFTM questionnaire, validated in Russia, was used to assess the HRQOL of patients on hemodialysis. A total of 723 patients were interviewed. Hemoglobin (Hb) levels were assessed in 442 patients based on outpatient records. To identify the relationship between Hb level and HRQOL scales, a correlation analysis was performed, as well as a HRQOL analysis in the three groups differing in hemoglobin levels (100; 100-120 and 120 g/l). Statistical data processing was carried by SPSS.22 and using parametric and nonparametric statistical methods. Results. Correlation relationship was revealed between Hb and HRQOL of patients on hemodialysis on the scales "symptoms/problems", "pain", "vital activity, energy" and "total physical component of health". According to the scales "symptoms/problems" and "vital activity, energy", higher rates were noted among patients with Hb higher than the target level, which confirms the recommendations concerning the possibility of achieving higher Hb among individual patients who have not serious concomitant diseases and cardiovascular complications in order to improve their quality of life. Conclusion. HRQOL assessment is important tool for planning and evaluating the effectiveness of anemia drug therapy among patients with CKD on hemodialysis.


  • Genetic profile of patients with atypical hemolytic uremic syndrome

    by E.S. Ivanova Ivanova, E.S. Stolyarevich Stolyarevich, O.N. Kotenko Kotenko, V.E. Vinogradov Vinogradov, L.YU. Artyukhina Artyukhina, N.F. Frolova Frolova, P.A. Shatalov Shatalov, V.V. Ilyinsky Ilyinsky, Moscow Ooo Genotech Llc

  • The use of neutralizing monoclonal antibodies against SARS-CoV-2 in hemodialysis patients

    by E.V. Volodina, N.F. Frolova, M.A. Lysenko, I.G. Kim, A.I. Ushakova, V.E. Vinogradov, S.S. Usatiuk, A.M. Nikitina, U.A. Markina, V.I. Chervinko, et al.

    Применение нейтрализующих моноклональных антител при SARS-CoV-2-инфекции у больных, получающих лечение гемодиализом